Meningococcal serogroup B is the leading cause of invasive meningococcal disease (IMD) in Canada. Although this condition is relatively rare, IMD is associated with significant morbidity and mortality. Meningococcal serogroup B immunization can protect patients from this serious infection. In this program, Dr. Kirk Leifso provides expert IMD insight and discusses the role of immunization against this endemic infection.
This program is developed in collaboration with Queen’s University.